Pseudomyxoma peritonei natural history, complications and prognosis

Jump to navigation Jump to search

Pseudomyxoma peritonei Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Pseudomyxoma peritonei from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pseudomyxoma peritonei natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pseudomyxoma peritonei natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pseudomyxoma peritonei natural history, complications and prognosis

CDC on Pseudomyxoma peritonei natural history, complications and prognosis

Pseudomyxoma peritonei natural history, complications and prognosis in the news

Blogs on Pseudomyxoma peritonei natural history, complications and prognosis

Directions to Hospitals Treating Pseudomyxoma peritonei

Risk calculators and risk factors for Pseudomyxoma peritonei natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

Pseudomyxoma peritonei is a rare disease characterized by the accumulation of mucinous ascites and mucinous tumor disseminated in the peritoneal cavity, mainly abdomen and pelvis; the disease almost always originates from primary appendiceal tumors and less commonly from the ovary and colon. In 2010, WHO published a classification which divides pseudomyxoma peritonei (PMP) into low and high grades. Cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (CRS/HIPEC) is the mainstay of treatment appendiceal pseudomyxoma peritonei (PMP).

Natural History

  • Pseudomyxoma peritonei (PMP) is an uncommon disease characterized by mucinous ascites in intraperitoneal cavities, it is originating from a low-grade mucinous neoplasm of the appendix, if left untreated, patients with pseudomyxoma peritonei may progress to develop abdominal or pelvic pain, bloating, abdominal distension, weight change, and infertility due to compression impact of tumor on visceral organs.
  • Psuedomyxoma peritonei tumour produces abundant mucins which accumulate because of to gravity effect in the mesentery, the greater and lesser omentum, and the under the diaphragm, around the liver and other visceral organs surfaces.
  • The optimal treatment is cytoreductive surgery (CRS) combined with hyperthermic Intraperitoneal chemotherapy (HIPEC).[1]

Prognosis

  • Prognosis of pseudomyxoma peritonei is generally good because of change in treatment modalities, mainly surgery techniques which developed by Sugarbaker. Traditional debulking surgery replaced by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy(HIPEC).[2]
  • Although pseudomyxoma peritonei is a neoplastic disease, it runs in a chronic, an indolent course with late invasion and only rare metastasis outside the peritoneum.
  • According to WHO classification, pseudomyxoma peritonei (PMP) divides into low and high grades, and the most common primary tumor arises from a low grade appendiceal mucinous neoplasm with good prognosis with higher survival rate based on their histological morphology, in contrast, tumors arising from colorectal neoplasm are usually high grades with bad prognosis.[3]

References

  1. Mittal R, Chandramohan A, Moran B (August 2017). "Pseudomyxoma peritonei: natural history and treatment". Int J Hyperthermia. 33 (5): 511–519. doi:10.1080/02656736.2017.1310938. PMID 28540829.
  2. Sugarbaker PH (April 2001). "Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome". Eur J Surg Oncol. 27 (3): 239–43. doi:10.1053/ejso.2000.1038. PMID 11373099.
  3. Carr, Norman J; Finch, Jenny; Ilesley, Ian Charles; Chandrakumaran, Kandiah; Mohamed, Faheez; Mirnezami, Alex; Cecil, Tom; Moran, Brendan (2012). "Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases". Journal of Clinical Pathology. 65 (10): 919–923. doi:10.1136/jclinpath-2012-200843. ISSN 0021-9746.


Template:WikiDoc Sources